The laboratory in Mozambique has successfully implemented the project.

Mozambique Laboratory Goes Live: Delivered IVD Reagent Menu Enters Routine Testing

a diagnostic laboratory in Mozambique has moved a newly delivered rapid-test menu into routine use — seven test configurations covering nine analytes across cardiac, critical-care, infectious-disease, gastric-screening and fertility testing, all run on a single benchtop workflow.

MOZAMBIQUE — September 2026 — The shipment has cleared, the boxes are open, and the tests are running. Bernardo, a diagnostics provider serving Maputo and the surrounding region, has confirmed receipt of its latest reagent order and moved the complete menu onto its routine bench. The photograph above was taken by the laboratory's own staff during the first week of use.

At a glance

Why menu breadth is the deciding factor in this market

Mozambique is consolidating its diagnostic capacity, and the direction of travel favours laboratories that can offer more tests from fewer platforms. A national laboratory network mapping exercise conducted with the Ministry of Health assessed 511 laboratories to identify critical gaps in the network and prioritise where capacity should be built next (ASLM, March 2026).

For a laboratory in that environment, the practical question is not "which single test can I run" but "how many clinical decisions can one bench support". Every additional analyte that requires a separate instrument, a separate reagent stream or a separate training cycle adds cost without adding capability. A consolidated menu changes the economics of the bench itself.

What was delivered

The menu confirmed in the customer's own photograph spans seven test configurations and nine analytes across five clinical areas:

Cardiovascular & thrombotic risk — Lp-PLA2, MPO and D-Dimer, covering vascular inflammation, plaque instability and clot formation / lysis.

Brain injury and critical care — S100-B.

Infection & sepsis — PCT/CRP combined configuration, pairing a specific bacterial-infection marker with a rapid inflammatory marker on one cartridge.

Gastric cancer screening — PG I / PG II, the standard serum pepsinogen pairing.

Fertility & ovarian reserve — AMH.

All configurations run on the same benchtop, cartridge-based workflow, with results returned in 2–15 minutes. For a laboratory managing referral volume, that matters in two directions at once: the bench absorbs a wider clinical menu without a second instrument, and each additional analyte is a marginal expansion rather than a new project.

From delivery to routine use

A delivery becomes an installed capability only when the bench staff trust the result. The deployment sequence for this order followed the standard protocol:

Incoming verification — cartridges received, lot numbers logged, storage conditions and expiry checked against the packing documentation.

Bench validation — control runs performed on the delivered lots before any patient specimen is tested.

Operator training — bench staff walked through cartridge handling, sample loading, result interpretation and the consumable changeover cycle.

Routine release — the menu moved into normal daily operation, which the laboratory's photograph confirms.

Every delivered lot carries its own QC release record and a traceable batch number, and manufacturing is held to GMP Certified Manufacturing standards. For procurement teams, the relevant point is not the certificate itself but what it makes possible downstream: predictable lot-to-lot behaviour, an audit trail when a health authority asks for one, and a documented basis for the laboratory to sign off on a new reagent line.

What this signals to distributors and laboratory groups

Orders like this one are a supply-chain statement rather than a single transaction. Three implications are worth weighing for distributors and multi-site laboratory groups:

Menu depth from one source. Five clinical areas from a single supplier removes the coordination cost of stitching together four or five vendors — one lead time, one documentation set, one point of accountability.

Continuity over one-off pricing. Reagent businesses live or die on whether the second, fifth and twentieth shipment match the first. Batch traceability and QC release at lot level are what make that repeatable.

Room to build a brand, not just resell. Private-label and OEM supply lets distributors put their own name on the menu while keeping a single manufacturing partner behind it. Documentation support is provided for regulatory submission in the destination market.

Expanding your rapid-testing menu

If you are building or extending a rapid-testing portfolio — cardiac, inflammation, sepsis, gastric screening or fertility — our team can map the configuration set against your clinical demand and volume profile, and confirm supply capacity, lead time and OEM options for your market.Our equipment currently supports 38 types of project inspections.

Contact our team → https://www.jiuhekit.com/

About Beijing Jiachuang Jiuhe Global Trade Co., Ltd.

Beijing Jiachuang Jiuhuo provides a one-stop solution for the production and supply of all products related to the medical industry for global laboratories, clinics and distributors. Our portfolio covers fluorescence immunoassay and point-of-care test menus across cardiovascular, inflammation, infectious disease, oncology screening and fertility, supported by GMP Certified Manufacturing, batch-level QC release and OEM / private-label supply.